Categories: News

T2 Biosystems to Report Second Quarter 2021 Financial Results on August 5, 2021

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

LEXINGTON, Mass., July 22, 2021 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results for the second quarter of 2021 after market close on Thursday, August 5, 2021. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. The call will also be available by dialing 1-877-407-9208 (U.S.) or 1-201-493-6784 (International) five to ten minutes prior to the start time.

About T2 Biosystems:
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel, the T2Resistance™ Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Cauris™ Panel, and T2Lyme™ Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens.

Media Contact:
Gina Kent, Vault Communications
gkent@vaultcommunications.com
610-455-2763

Investor Contact:
Philip Trip Taylor, Gilmartin Group
philip@gilmartinIR.com
415-937-5406

Staff

Recent Posts

WELL Health Announces Delay in Filing of Annual Audited Financial Statements Due to Matter Related to US Subsidiary Circle Medical

VANCOUVER, BC, March 28, 2025 /PRNewswire/ - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF)…

7 hours ago

Antithrombin Blood Test from Siemens Healthineers Now FDA Cleared as a Companion Diagnostic for Qfitlia, a Sanofi Hemophilia Therapy

The assay now can measure antithrombin (AT) activity levels for people treated with Qfitlia Measuring…

13 hours ago

SimonMed Imaging Provides Notice of Security Incident

SCOTTSDALE, Ariz., March 28, 2025 /PRNewswire/ -- SimonMed Imaging confirmed that it experienced a data incident…

13 hours ago

Sohar Health Lands $3.8M to Open the Front Door to Faster, Fairer Care

Kindred Capital backs Sohar Health's mission to remove one of care's biggest hidden barriers and…

13 hours ago

FemTech Leaders Willow and Elvie Unite to Advance the Next Revolution in Maternal Health

Willow acquires Elvie to develop a global multi-category platform offering a diverse range of maternal…

13 hours ago

Dräger and VirtualiSurg receive Obsidian Award for Babyleo XR extended reality simulator.

Award honors groundbreaking innovations in extended reality across reality platforms, spanning hardware, software and content…

13 hours ago